Rezeptorszintigraphie mit ¹¹¹In-Pentetreotid beiendokrinen gastroenteropankreatischenTumoren

Zusammenfassung

Die Rezeptorszintigraphie mit ¹¹¹In-Pentetreotid ist ein komplementäres bildgebendesVerfahren mit einer Sensitivität von 88%, um bei Patienten mitklinischen und biochemischen Symptomen eines endokrinen Tumors desGastrointestinaltraktes oder des Pankreas den Primärtumor und dessen Metastasen zu lokalisieren. Als Ganzkörperszintigraphie erfaßt sie jede Körperregionund stellt auch kleine Tumoren dar, die mit den übrigen bildgebendenVerfahren nicht oder nur schwer zu entdecken sind. Bei 104 Patienten mit GEP-Tumoren oder nach operativer Entfernung eines solchen Tumors erwiessich die Rezeptorszintigraphie als dem Ultraschall und der Computertomographie bei 34% in der Aussagekraftüberlegen, bei 52% als gleich und bei 14%als unterlegen.

Summary

Receptor scintigraphy with ¹¹¹ln-pentetreotide is a complementary imaging technique with a sensitivity of 88% for the localization of the primary tumor and its metastases in patients presenting with the clinical and biochemical symptoms of an endocrine tumor of the gastrointestinal tract or the pancreas. As a whole-body scintigraphic technique it covers all body regions and is also able to reveal small tumors which can only be detected with difficulty or not at all by the usual imaging methods. In 104 patients with GEP tumors or after operative removal of such tumors, receptor scintigraphy proved to be superior to ultrasound and computed tomography in 34%, equal in 52% and inferior in14% of the cases.

Schlüsselwörter

Rezeptorszintigraphie - GEP-Tumoren - ¹¹¹In-Pentetreotid

Key words

Receptor scintigraphy - GEP tumors - ¹¹¹In-pentetreotide

• LITERATUR

• 1 Arnold R, Neuhaus C, Benning R, Schwerk WB, Trautmann ME, Joseph K, Bruns C. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastro-entero-pancreatic (GEP) tumors. Wld J Surg, in press..
• 2 Arnold R, Neuhaus C, Trautmann ME. Therapie endokriner gastroenteropankreatischer Tumoren mit dem Somatostatin-Analogon Octreotid. Dtsch med Wschr 1992; 117: 1067-71.
• 3 Bakker WH, Albert R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP. (¹¹¹In -DTPA-D-Phe’)-octreotide a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sei 1991; 49: 1583-91.
• 4 Bakker WH, Krenning EP, Breeman WAP, Koper JW, Kooij PPM, Lameris JS, Reubi J-C, Visser TJ, Lamberts SWJ. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism and binding to somatostatin receptor-positive tumours in man. J Nucl Med 1991; 32: 1184-9.
• 5 Bakker WH, Krenning EP, Breeman WAP, Koper JW, Kooji PPM, Reubi J-C, Klijn JG, Visser TJ, Docter R, Lamberts SWJ. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990; 31: 1501-9.
• 6 Bakker WH, Krenning EP, Reubi J-C, Breeman WAP, Setyonohan B, de Jong M, Kooji PPM, Bruns C, van Hagen PM, Marbach P, Visser TJ, Pless J, Lamberts SWJ. In vivo application of (¹¹¹In-DTPA-DPhe¹-octreotide for detection of somatostatin receptor-positive tumours in rats. Life Sei 1991; 49: 1593-601.
• 7 Bauer W, Briner U, Döpfner W, Haller R, Marbach P, Petcher TJ, Pless J. SMS 201-995. A very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sei 1982; 31: 1133-40.
• 8 Dörr UK, Wurm K, Höring E, Guzman G, Räth U, Bihl H. Diagnostic reliability of Somatostatin receptor scintigraphy during continous treatment with different Somatostatin analogs. In: Somatostatin receptor imaging. Bihl H, Dörr U. (eds). Hormone Met Res, Suppl 27. Stuttgart: Thieme Med Publ; 1993: 36-42.
• 9 Gordon P. NIH Conference. Somatostatin and somatostatin-analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and nonneoplastic diseases of the gut. Ann Intern Med 1989; 110: 35.
• 10 Höring E, Gaisberg U v. Neuroendokrine Tumoren des Pankreas und Gastrointestinaltrakts. Dtsch Med Wschr 1991; 116: 1197-202.
• 11 Joseph K, Stapp J, Reinecke J, Höffken H, Benning R, Neuhaus C, Trautmann ME, Schwerk WB, Arnold R. Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren. Dtsch Med Wschr 1992; 117: 1025-8.
• 12 Joseph K, Stapp J, Reinecke J, Skamel HJ, Höffken H, Neuhaus Ch, Lenze H, Trautmann ME, Arnold R. Receptor scintigraphy with ¹¹¹In-Pentetreotide for endocrine gastroenteropancreatic tumors. In: Somatostatin receptor imaging. Bihl H, Dörr U. (eds). Hormone Met Res, Suppl 27. Stuttgart: Thieme Med Publ; 1993: 28-35.
• 13 Kutz E, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21 (Suppl. 119) 65.
• 14 Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooji PPM, Ausema L, Lameris JS, Reubi J-C, Lamberts SWJ. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 01: 242-4.
• 15 Krenning EP, Bakker WH, Kooji PPM, Breeman WAP, Oei HY, de Jong M, Reubi J-C, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hägen PM, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with Indium-111-DTPA-D-Phe-l-Octreotide in man: metabolism, dosimetry and comparison with Iodine-123-Tyr-3-Octreotide. J Nucl Med 1992; 33: 652-8.
• 16 Krenning EP, Kwekkeboom DJ, Oei HY, Reubi J-C, Van Hägen PM, Kooji PPM, Reijs AEM, Lamberts SWJ. Somatostatin receptor imaging of endocrine gastrointestinal tumors. Schweiz Med Wochenschr 1992; 122: 634-7.
• 17 Kvols LK, Moertcl CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663-6.
• 18 Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993; 20: 283-92.
• 19 Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Splinter TAW, Kho GS, Lamberts SWJ. Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. J Nucl Med 1991; 32: 1845-8.
• 20 Lamberts SWJ, Bakker WH, Reubi J-C, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-9.
• 21 Lamberts SWJ, Hofland LJ, van Koetsveld PM, Reubi J-C, Bruining HA, Bakker WH, Krenning EP. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization and therapy. J Clin Endocrinol Metab 1990; 71: 566-74.
• 22 Lamberts SWJ, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450-82.
• 23 Moertel CG. An Odyssey in the land of small tumors. J Clin Oncol 1987; 05: 1503.
• 24 Reichlin S. Somatostatin. N Engl J Med 1983; 309 1495-501, 1556-63.
• 25 Reubi J-C, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-73.
• 26 Reubi J-C, Häcki WH, Lamberts SWJ. Hormone-producing gastro-intestinal tumours contain a high density of somatostatin receptors. J Clin Endocrinol 1987; 65: 1127-34.
• 27 Reubi J-C, Kvols L, Krenning EP, Lamberts SWJ. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39: 78-81.
• 28 Reubi J-C, Landolt AM. High incidence of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984; 59: 1148-51.
• 29 Reubi J-C, Maurer R, Klijn JGM, Stefanko SZ, Foekens JA, Glaauw G, Blankenstein MA, Lamberts SWJ. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 1986; 63: 433-8.
• 30 Reubi J-C, Probst A, Cortes R, Palacios JM. Distinct topographical localisation of two somatostatin receptor subpopulations in the human cortex. Brain Res 1987; 406: 391.
• 31 Schally AV. Oncological application of somatostatin analogues. Cancer Res 1988; 48: 6977-85.
• 32 Stöckmann F, Creutzfeldt W. Behandlung gastrointestinaler neuroendokriner Tumoren mit dem Somatostatin-Analog Octreotide (Sandostatin). Z Gastroenterol 1988; 26: 665.
• 33 Sreedharan SP, Kodama KT, Peterson KE. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989; 264: 949-53.
• 34 Srkalovic G, Cai RZ, Schally AV. Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab 1990; 70: 661.
• 35 Taylor JE, Coy DH, Moreau JP. High affinity binding of (125J-Tyr11) somatostatin-14 to human small cell lung carcinoma (NCI-H69). Life Sei 1988; 43: 421.
• 36 Wiedenmann B, Rath U, Rädsch R, Becker F, Kommereil B. Tumor regression of anilealcarcinoid under the treatment with the somatostatin analogue SMS 201-995. Klin Wschr 1988; 66: 75-7.